Tatva Chintan Pharma Chem Limited Q2FY27 Investor Presentation Released
Tatva Chintan Pharma Chem Limited released its Q2FY27 investor presentation. H1FY27 revenue surged 60% YoY to ₹3,844 million, with PAT up 126% to ₹374 million. Q2FY27 revenue grew 76% YoY to ₹2,173 million, and PAT increased 116% YoY to ₹215 million. The company achieved its highest-ever quarterly turnover, driven by strong performance across its product segments.
The release of an investor presentation detailing strong financial results and future growth strategies, including record turnover and significant YoY growth, is material information for investors and analysts.
The announcement highlights record quarterly turnover, significant year-over-year revenue and profit growth, and positive developments across various business segments, indicating strong operational and financial performance.
Tatva Chintan Pharma Chem Limited has released its Investor Presentation for the quarter and half-year ended September 30, 2026. The presentation highlights a landmark quarter with the Company achieving its highest-ever quarterly turnover. This performance is attributed to the increasing commercial traction of its businesses, the widening relevance of its specialized chemistries, and sustained efforts in building a stronger business platform.
The Chairman and Managing Director's message emphasizes growth across a diversified portfolio, including established business in SDA and newer initiatives in energy storage, and agro and pharma intermediates. While the company achieved significant operating leverage with a decrease in employee and other expenses, EBITDA remained at similar levels due to temporary phenomena like erratic short supplies in some solvents leading to price increases of 60%-100%, and a rampant increase in global freights (over 100% in certain sectors of the US and Europe). These trends are expected to normalize within the third quarter, with a foreseen continuation of revenue growth momentum and a resumption of healthy EBITDA margins.
The presentation details progress across various product segments: Phase Transfer Catalysts (PTC) continue to strengthen their franchise due to demand for process efficiency and sustainable methods. Structured Directing Agents (SDA) are benefiting from the implementation of EURO 7 emission standards. In Electrolyte Salts and Solutions (ESS), energy storage remains an attractive avenue, with engagements with existing customers, progress in hybrid-battery commercialization, and scaling up of additional products. The Pharma, Agro, and Speciality Chemicals (PASC) business is gaining momentum with well-performing agro products and contributing pharma products. Semiconductor Chemicals show encouraging progress across five products in the development portfolio.
Financially, for H1FY27, Revenue from Operations increased by 60% YoY to ₹3,844 million, and EBITDA (Excl. Other Income) rose by 85% YoY to ₹730 million, with an EBITDA Margin of 19%. PAT increased by 126% YoY to ₹374 million. For Q2FY27, Revenue from Operations grew by 76% YoY to ₹2,173 million, EBITDA (Excl. Other Income) increased by 83% YoY to ₹407 million with an EBITDA Margin of 19%, and PAT increased by 116% YoY to ₹215 million.
The company's new greenfield project is progressing as planned, which will support future growth by providing additional manufacturing capacity for existing businesses and new product commercialization. Tatva Chintan is committed to building a larger, more diversified, and technologically differentiated business focused on sustainable earnings.
What to do with a filing like this
Tatva Chintan Pharma Chem Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Tatva Chintan Pharma Chem Limited. Read the original for the full detail.